Literature DB >> 7189523

A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine.

M O Thorner, H F Schran, W S Evans, A D Rogol, J L Morris, R M MacLeod.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7189523     DOI： 10.1210/jcem-50-6-1026

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  23 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.

Authors:  I Halperin; M D Rodriguez; C Cardenal; R Casamitjana; M J Martinez Osaba; V Lienas; E Vilardell
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

4.  Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model.

Authors:  J Grevel; J Brownell; J L Steimer; R C Gaillard; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

5.  Reduction of body fat stores by inhibition of prolactin secretion.

Authors:  A H Cincotta; A H Meier
Journal:  Experientia       Date:  1987-04-15

6.  Bromocriptine and sulpiride competitively inhibit estrogen binding to its receptor in the adrenal gland.

Authors:  I A Lüthy; R S Calandra
Journal:  Experientia       Date:  1986-02-15

Review 7.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

8.  Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients.

Authors:  A M Mancini; M Barontini; I Armando; G Levin; A Kleiman; J Razumny; I Molocznik
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

9.  Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.

Authors:  N P Verhoeff; F J Bemelman; W M Wiersinga; E A van Royen
Journal:  Eur J Nucl Med       Date:  1993-06

Review 10.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.